New collaboration to develop gene therapies for heart failure

Cardiomyopathy is a disease of the heart muscle that can lead to heart failure in children and adults. Around 50% of cases are caused by a single-gene defect and there is currently no cure. 

The collaboration and licence agreement with DiNAQOR will leverage UCL’s leading expertise in gene therapy, including the research of Professor Thomas Voit at the UCL Great Ormond Street Institute of Child Health.

The licence agreement was facilitated by UCL’s technology commercialisation company, UCL Business Ltd (UCLB), part of UCL Innovation & Enterprise. You can find out more on UCLB’s website. 

Photo by Mary Hinkley © UCL Creative Media Services